Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance

Br J Haematol. 2010 Jul;150(2):240-2. doi: 10.1111/j.1365-2141.2010.08187.x. Epub 2010 Mar 19.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage*
  • Benzamides
  • Cancer Vaccines / therapeutic use*
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Cancer Vaccines
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate